The objective of this study is to validate the specific questionnaire for Hepatitis B HBQOL (Hepatitis Quality Life Instrument, version 1.0) Brazilian version, in addition testing its applicability patients with hepatitis under treatment and comparing quality life between using first-line drugs (tenofovir entecavir). For validation, back-translation technique was used a sample 47 patients. Fact...

We describe our experience with tenofovir-based antiretroviral therapy in seven HIV-infected children after failure of first line antiretroviral drugs, or due to adverse effects to other antiretrovirals. For follow-up period of average 3.4 years, none had adverse effects or failure of treatment, indicating that tenofovir has good renal and gastrointestinal safety profile in HIV-infected Indian ...

Kidney injury (defined as the presence of albuminuria, proteinuria, glycosuria [without hyperglycemia], hematuria, and/or renal hypophosphatemia) is an emerging problem in human immunodeficiency virus (HIV)-infected patients, although few data are available on the role of protease inhibitors (PIs) in this condition.To determine the time to kidney injury in a cohort of HIV-infected patients rece...

INTRODUCTION Recent WHO guidelines for resource-limited settings recommend tenofovir in first-line antiretroviral therapy (ART) yet there are suggestions that patients receiving nevirapine with tenofovir have worse outcomes than those receiving efavirenz. We sought to compare outcomes among those taking nevirapine vs. efavirenz with tenofovir and lamivudine. METHODS We analyzed data on ART na...

BACKGROUND Tenofovir (TDF) has been associated with renal function deterioration, but local data regarding the incidence and risk factors for this adverse event were lacking. OBJECTIVES To determine the incidence of nephrotoxicity in HIV-infected patients on tenofovir-based regimens and to evaluate risk factors involved in tenofovir-associated renal function decline. METHODS This is a singl...

OBJECTIVES To compare the response to hepatitis C virus (HCV) therapy among human immunodeficiency virus (HIV)/HCV co-infected patients receiving a nucleos(t)ide reverse transcriptase inhibitor [N(t)RTI] backbone consisting of abacavir plus lamivudine with that observed in subjects who receive tenofovir plus lamivudine or emtricitabine. METHODS A total of 256 subjects, enrolled in a cohort of...

AIM To make efficacy and safety comparison of telbivudine-raodmap and tenofovir-roadmap in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) patients. METHODS This was the first prospective, randomised, two-arm, open-label, non-inferiority study in HBeAg-negative CHB patients that compared telbivudine and tenofovir administered as per roadmap concept. Patients were treated up t...

State University, Columbus, Ohio, Capital Medical Associates, Washington DC, DC, The Dr James J Rahal Jr. Division of Infectious Disease, NewYork-Presbyterian Queens, Flushing, New York, La Playa Medical Group, San Diego, California, AIDS Healthcare Foundation, Los Angeles, California, APEX Research, Denver, Colorado, Atlanta Infectious Disease Group PC, Atlanta, Georgia, Gilead Sciences, Foste...

We describe a 49-year-old man with human immunodeficiency virus infection and stable chronic renal insufficiency who developed acute oliguric renal failure and severe lactic acidosis and who died several weeks after tenofovir was added to an antiretroviral regimen that included didanosine. Although the role of tenofovir in precipitating acute renal failure is unclear, progressive accumulation o...